IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY
I TE KŌTI MATUA O AOTEAROA TE WHANGANUI-A-TARA ROHE
CIV-2025-485-000053
[2025] NZHC 2657
UNDER the Patents Act 2013 and Parts 20 and 22 of the High Court Rules 2016 IN THE MATTER OF
an appeal against a decision of the Commissioner of Patents
BETWEEN
PHARMALINK INTERNATIONAL LIMITED
Appellant
AND
PHARMAZEN LIMITED
First Respondent
COMMISSIONER OF PATENTS
Second Respondent
Hearing: 11 – 12 August 2025 Counsel:
GF Arthur KC for Appellant
JM Glover and JP Rogers for First Respondent
Judgment:
12 September 2025
JUDGMENT OF DOWNS J
This judgment was delivered by me on Friday, 12 September 2025 at 3 pm pursuant to r 11.5 of the High Court Rules 2016.
Registrar/Deputy Registrar
Solicitors/Counsel: Buddle Findlay, Auckland. James & Wells, Auckland. Crown Law, Wellington.
GF Arthur KC, Wellington. JM Glover, Auckland.
PHARMALINK INTERNATIONAL LTD v PHARMAZEN LTD [2025] NZHC 2657 [12 September 2025]
Table of Contents
The appeal [1]
Appellate approach [2]
Background [3]
Synergy [6]
Example 2 [9]
Example 3 [16]
Do examples 2 and 3 exhibit synergy? [21]
Does the specification disclose the invention in a manner clear and complete enough for the invention to be performed by a person skilled in the art? Is the application supported by the material disclosed in
the specification? [33]
Patient study (example 4) [55]
Is amendment of a claim permissible on appeal? [59]
Krill species [63]
Mussel species [65]
The definition of “about” [66]
Is the invention novel? [84]
It is obvious to combine the ingredients in the claimed ratios? [96]
Summary of conclusions [108]
Result [109]
Costs [110]
The appeal
[1] This judgment addresses a patent appeal. As is so often the case, the subject matter is technical. In what follows, I attempt to explain, as simply as possible, the applicable science. Some technical language is, however, unavoidable, including in relation to patent law.
Appellate approach
[2] An appeal in this context is a rehearing but, as appellant, Pharmalink International Ltd1 must identify error on the part of the Commissioner of Patents or persuade me to a different conclusion from him.2
1 Pharmalink.
2 Austin, Nichols & Co Inc v Stichting Lodestar [2007] NZSC 103, [2008] 2 NZLR 141 at [16].
Background
[3] Pharmalink applied for a patent in relation to an alleged invention: the anti-inflammatory effect of green-lipped mussel lipid extract with krill oil. Each ingredient has long been recognised as having anti-inflammatory properties. No one, however, had seemingly contemplated the two being combined or taken together to reduce inflammation beyond the sum of their parts. This introduces the key concept: synergy arises when ingredients produce just such an outcome. For example, an ingredient that reduced inflammation by two units with another that reduced it by three would produce a synergistic effect if together, the reduction were six units. A reduction of five units would be additive, not synergistic.
[4] Pharmazen Ltd3 opposed Pharmalink’s application on a multiplicity of grounds. The Assistant Commissioner4 dismissed several objections but upheld five, and…
Keep reading for free
Create a free CaseChat account to read Pharmalink International Ltd v Pharmazen Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] NZHC 2657
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.